AimsClozapine is licensed for treatment-resistant psychosis and remains underutilised. This
may berelated to the stringent haematological monitoring requirements that are mandatory …

Purpose Although clozapine was Food and Drug Administration (FDA) approved more than
3 decades ago, major barriers and gaps in knowledge continue to prevent its effective and …

Clozapine is the only antipsychotic that is effective in treatment-resistant schizophrenia.
However, in certain clinical situations, such as the emergence of serious adverse effects, it is …

Despite its enduring relevance as the single most effective and important evidence-based
treatment for schizophrenia, underutilization of clozapine remains considerable. To a …

Background Clozapine is uniquely effective in treatment-resistant psychosis. In the UK,
patients must discontinue clozapine indefinitely if they are placed on the Central Non …

Abstract Background and Purpose Clozapine is an effective antipsychotic for treatment‐
resistant schizophrenia, but its discontinuation leads to discontinuation syndrome/catatonia …

Only about 50% of patients with treatment-resistant schizophrenia respond to clozapine, and
many more patients continue to experience ongoing and prominent negative symptoms …

For several decades, the dopamine hypothesis contributed to the discovery of numerous
typical and atypical antipsychotics and was the sole hypothesis for the pathophysiology of …

Clozapine is listed as one of the most effective antipsychotics and has been approved for
treating treatment-resistant schizophrenia (TRS); however, several type A and B adverse …

Slower tapering of antipsychotics may provide time for adaptations made to the presence of
the medications to resolve, thus reducing the disruption to homeostatic equilibrium caused …